Application of Bergapten or isomer thereof in preparation of product for improving skin aging and / or promoting skin repair

Abstract

The invention relates to application of Bergapten or an isomer thereof in preparation of a product for improving skin aging and / or promoting skin repair. A large number of experiments prove that Bergapten or an isomer thereof can improve skin aging and / or promote skin repair and has good safety, and the specific expression is as follows: Bergapten can activate expression of SIRT1 protein and is superior to that of an existing activator resveratrol; the Bergapten can obviously inhibit the reduction of the content of various collagens in skin keratinocytes caused by UV light aging stimulation; the Bergapten can be used for promoting the healing capability of cell scratches. In conclusion, the Bergapten or the isomer thereof has great clinical application prospect and value in preparation of products for improving skin aging and / or promoting skin repair.

Description

Technical Field

[0001] The present application relates to the field of biomedical technology, and in particular to an application of Bergapten or its isomers in the preparation of products for improving skin aging and / or promoting skin repair. Background Art

[0002] The skin is the largest organ in the human body, and its main function is to protect internal tissues from the external environment. However, with the increase of age and the influence of external factors such as ultraviolet (UV) radiation, the skin will gradually show aging phenomena, such as wrinkles, spots, and sagging. This skin aging is mainly caused by the degradation of collagen and structural proteins in the skin, which leads to sagging of the skin. The loss or lack of collagen will also affect the overall appearance of the skin. Existing anti-aging products mostly use chemical ingredients or plant extracts, but the effects of these products are often limited and may be accompanied by certain side effects. In recent years, SIRT1 (silent information regulator 2-related enzyme 1), as an important aging-related protein, has gradually become a research hotspot. It exists in eukaryotic and prokaryotic organisms. It plays an important physiological role in cell survival and proliferation. Its dysfunction involves physiological activities such as aging, as well as the occurrence and development of various diseases such as tumors, diabetes, cardiovascular diseases, chronic inflammation and some metabolic diseases. At the skin organ level, SIRT1 can promote the proliferation and differentiation of keratinocytes; it can also improve the aging of human skin fibroblasts caused by ultraviolet radiation and prevent UV-induced photoaging by inhibiting the activity of matrix metalloproteinases and reducing collagen degradation. Summary of the invention

[0003] Based on this, the purpose of the present application includes providing a use of Bergapten or its isomers in the preparation of products for improving skin aging and / or promoting skin repair.

[0004] The technical solution of this application is as follows:

[0005] The present invention provides application of Bergapten or its isomers in preparing products for improving skin aging and / or promoting skin repair.

[0006] In one embodiment, the product includes cosmetics, food and medicine.

[0007] In one embodiment, the cosmetics include one or more of lotion, cream, emulsion, essence, facial mask and eye cream;

[0008] The food includes one or more of functional food, beverage, health product and nutritional supplement.

[0009] In one embodiment, the dosage form of the drug includes oral solution, liquid suspension, powder, tablet, capsule, powder, mixture, pill, granule, syrup, plaster, suppository, aerosol, ointment or injection.

[0010] In one embodiment, the product further comprises auxiliary materials.

[0011] In one embodiment, the administration of the product includes oral administration and / or topical administration.

[0012] In one embodiment, the external application includes local topical administration and / or systemic transdermal administration.

[0013] In one embodiment, the improvement of skin aging includes one or more of improving skin photoaging, improving wrinkles, improving pigmentation, and improving skin sagging.

[0014] In one embodiment, the promoting skin repair refers to activating the expression of SIRT1; and / or

[0015] The said promoting skin repair refers to promoting the expression of collagen; and / or

[0016] The said promoting skin repair refers to promoting cell healing.

[0017] In one embodiment, the collagen is one or both of Collagen Ⅰ and Collagen Ⅲ.

[0018] Compared with the prior art, this application has the following beneficial effects:

[0019] The inventors of the present application have confirmed through a large number of experiments that Bergapten or its isomers can improve skin aging and / or promote skin repair, and have good safety, which is specifically manifested as follows: Bergapten can activate the expression of SIRT1 protein, and is superior to the existing activator resveratrol; Bergapten can significantly inhibit the reduction of various collagen content in skin keratinocytes caused by UV light aging stimulation; Bergapten can promote the healing ability of cell scratches. In summary, Bergapten or its isomers have great clinical application prospects and value in the preparation of products that improve skin aging and / or promote skin repair. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] In order to more clearly illustrate the specific implementation methods of the present application or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.

[0021] Figure 1 This is a graph showing the toxicity test results of Bergapten on immortalized keratinocytes of human skin in Example 1, wherein the abscissa represents the concentration of Bergapten and the ordinate represents the cell survival rate.

[0022] Figure 2 This is a diagram showing the activation effect of Bergapten on SIRT1 protein in Example 1, wherein no treatment was performed as the control group, UV was the model group, resveratrol was the positive drug control group, and Bergapten was the drug treatment group.

[0023] Figure 3 This is a diagram showing the promoting effect of Bergapten on the expression of various collagens in Example 1, wherein no treatment was performed as the control group, UV was the model group, resveratrol was the positive drug control group, and Bergapten was the drug treatment group.

[0024] Figure 4 This is a graph showing the healing promoting effect of Bergapten on human skin immortalized keratinocytes after scratching in Example 1, wherein no treatment was performed as the control group, UV was the model group, UV+resveratrol was the positive drug control group, and UV+Bergapten was the drug treatment group. DETAILED DESCRIPTION

[0025] In order to make the above-mentioned purposes, features and advantages of the present application more obvious and easy to understand, the specific implementation methods of the present application are described in detail below. In the following description, many specific details are set forth to facilitate a full understanding of the present application. However, the present application can be implemented in many other ways different from those described herein, and those skilled in the art can make similar improvements without violating the connotation of the present application, so the present application is not limited by the specific embodiments disclosed below.

[0026] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which this application belongs. The terms used herein in the specification of this application are only for the purpose of describing specific embodiments and are not intended to limit this application.

[0027] Unless otherwise specified or incompatible herewith, the terms and phrases used herein shall have the following meanings:

[0028] As used herein, "pharmaceutically acceptable" refers to those ligands, materials, compositions, and / or dosage forms that are suitable for administration to a patient within the scope of sound medical judgment and commensurate with a reasonable benefit / risk ratio.

[0029] Herein, "pharmaceutically acceptable salt" refers to a salt suitable for use as a drug formed by any compound in the structure shown and an acid or base. Pharmaceutically acceptable salts include inorganic salts and organic salts. Among them, one type of salt is a salt formed by the compound of the present application and an acid. Acids suitable for forming salts include but are not limited to: inorganic acids such as hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, nitric acid, and phosphoric acid; organic acids such as formic acid, acetic acid, trifluoroacetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, benzoic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, and naphthalenesulfonic acid; and amino acids such as proline, phenylalanine, aspartic acid, and glutamic acid. Another type of salt is a salt formed by the compound of the present application and a base. Suitable bases for forming salts include but are not limited to alkali metal salts (such as sodium salts or potassium salts), alkaline earth metal salts (such as magnesium salts or calcium salts), ammonium salts (such as lower alkanolammonium salts and other pharmaceutically acceptable amine salts), such as methylamine salts, ethylamine salts, propylamine salts, dimethylamine salts, trimethylamine salts, diethylamine salts, triethylamine salts, tert-butylamine salts, ethylenediamine salts, hydroxyethylamine salts, dihydroxyethylamine salts, trihydroxyethylamine salts, and amine salts formed from morpholine, piperazine, and lysine, respectively.

[0030] As used herein, "pharmaceutically acceptable carrier" refers to a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material. As used herein, the language "pharmaceutically acceptable carrier" includes buffers, sterile water for injection, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are compatible with drug administration. Each carrier must be "pharmaceutically acceptable" in the sense of being compatible with the other ingredients in the formulation and not harmful to the patient. Suitable examples include, but are not limited to: (1) sugars such as lactose, glucose and sucrose; (2) starches such as corn starch, potato starch and substituted or unsubstituted β-cyclodextrins; (3) cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients such as cocoa butter and suppository waxes; (9) oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn starch, etc. Rice oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerol, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffers, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethanol; (20) phosphate buffered saline; (21) other non-toxic compatible substances used in pharmaceutical preparations.

[0031] As used herein, "one or more" refers to any one, any two, or any two or more of the listed items.

[0032] Herein, the optional scope of "and / or", "or / and", and "and / or" includes any one of two or more relevant listed items, and also includes any and all combinations of the relevant listed items, wherein said any and all combinations include any two relevant listed items, any more relevant listed items, or a combination of all relevant listed items. (It should be noted that when at least three items are connected by at least two conjunctions selected from "and / or", "or / and", and "and / or", it should be understood that in the present application, the technical solution undoubtedly includes technical solutions that are all connected by "logical AND", and also undoubtedly includes technical solutions that are all connected by "logical OR". For example, "A and / or B" includes three parallel solutions of A, B and A+B. For another example, the technical solution of "A, and / or, B, and / or, C, and / or, D" includes any one of A, B, C, and D (that is, technical solutions that are all connected by "logical OR"), and also includes any and all combinations of A, B, C, and D, that is, a combination of any two or any three of A, B, C, and D, and also includes a combination of four items of A, B, C, and D (that is, a technical solution that is all connected by "logical AND").)

[0033] Herein, "further", "further", "particularly" and the like are used for descriptive purposes to indicate differences in content, but should not be construed as limiting the scope of protection of this application.

[0034] In this application, when it comes to numerical ranges, unless otherwise specified, the above numerical ranges are deemed to be continuous and include the minimum and maximum values ​​of the range, as well as each value between such minimum and maximum values. Further, when a range refers to an integer, each integer between the minimum and maximum values ​​of the range is included. In addition, when multiple ranges are provided to describe features or characteristics, the ranges can be merged. In other words, unless otherwise specified, all ranges disclosed herein should be understood to include any and all subranges included therein.

[0035] Only some numerical ranges are specifically disclosed herein. However, any lower limit can be combined with any upper limit to form an undefined range; and any lower limit can be combined with other lower limits to form an undefined range, and any upper limit can be combined with any other upper limit to form an undefined range. In addition, each separately disclosed point or single value itself can be combined with any other point or single value as a lower limit or upper limit or with other lower limits or upper limits to form an undefined range. The use of numerical ranges represented by endpoints includes all numbers within the range and any range within the range, for example, 1 to 5 includes 1, 1.1, 1.3, 1.5, 2, 2.75, 3, 3.80, 4 and 5, etc.

[0036] The percentage contents involved in this application, unless otherwise specified, refer to mass percentage for solid-liquid mixing and solid-solid mixing, and refer to volume percentage for liquid-liquid mixing.

[0037] The percentage concentrations mentioned in this application, unless otherwise specified, refer to the final concentration, which refers to the percentage of the added component in the system after the addition of the component.

[0038] The temperature parameters in this application, unless otherwise specified, allow both constant temperature treatment and treatment within a certain temperature range. The constant temperature treatment allows the temperature to fluctuate within the accuracy range controlled by the instrument. Fluctuations within the range of ±5°C, ±2°C, ±1°C, ±0.5°C, ±0.4°C, ±0.3°C, ±0.2°C, and ±0.1°C are allowed. Normal temperature or room temperature in this application refers to no temperature control operation, generally 4°C~35°C, preferably 20±5°C.

[0039] In the present application, the technical features described in an open manner include closed technical solutions composed of the listed features, and also include open technical solutions containing the listed features.

[0040] Skin aging is a complex process. On a macroscopic level, skin aging manifests itself as fine lines, loss of elasticity, orange peel-like changes or dull skin, and reduced thickness of the epidermis and dermis. On a microscopic level, typical features of skin aging include epidermal atrophy, reduced basal keratinocyte mitotic rate, decreased proliferation capacity and cell senescence, as well as atrophy of the dermal extracellular matrix and changes in the physiological properties of connective tissue.

[0041] Bergapten is called bergamot lactone in Chinese, also known as 5-methoxypsoralen, with a chemical formula of C 12 H8O4, the structural formula is as follows: . Studies have shown that Bergapten is a natural anti-inflammatory and anti-tumor agent that can inhibit mouse and human CYP isoforms, can be photoactivated, can cross-link with DNA, covalently modify proteins and lipids, and thus inhibit cell replication. Bergapten can deplete ERα from tamoxifen-sensitive and resistant breast cancer cells, thereby restoring the effect of membrane signaling targeting ERα and its mitogenic potential. Bergapten can effectively protect C57BL / 6J mice from acetaminophen (APAP)-induced hepatotoxicity, has antioxidant activity, and does not cause liver damage at protective doses. However, no studies have shown that Bergapten can affect the expression of the aging-related protein SIRT1 and its function in skin protection.

[0042] Based on this, the present invention provides the use of Bergapten or its isomers in preparing products for improving skin aging and / or promoting skin repair.

[0043] In some of these examples, the product also includes excipients.

[0044] In some examples, the product is administered orally and / or topically.

[0045] In some examples, the external use includes local topical administration and / or systemic transdermal administration.

[0046] In some examples, the products include cosmetics, food, and medicines.

[0047] In some of the examples, the cosmetics include one or more of lotion, cream, emulsion, essence, facial mask and eye cream.

[0048] In some examples, the food includes one or more of functional food, beverage, health product and nutritional supplement.

[0049] In some examples, the dosage form of the drug includes oral solution, liquid suspension, powder, tablet, capsule, powder, mixture, pill, granule, syrup, plaster, suppository, aerosol, ointment or injection. It is understandable that the drug of the present application can be added with different pharmaceutically acceptable excipients to prepare suitable clinical dosage forms, which include but are not limited to the dosage forms described herein.

[0050] In some of these examples, the drug can be administered using a suitable route of administration based on clinical needs. It can be understood that the routes of administration of the drug include intravenous injection, intraperitoneal injection, intramuscular injection, subcutaneous injection, oral administration, sublingual administration, nasal administration or transdermal administration.

[0051] In some examples, the drug includes an active ingredient, Bergapten, and a pharmaceutically acceptable excipient. Further, the pharmaceutically acceptable excipient includes, but is not limited to, a pharmaceutically acceptable salt, a diluent, a wetting agent, a binder, a disintegrant, a lubricant, a color and flavor regulator, a solvent, a solubilizer, a cosolvent, an emulsifier, an antioxidant, a metal complexing agent, an inert gas, a preservative, a local analgesic, a pH regulator, an isotonic or isotonic regulator, and the like.

[0052] In some examples, the improving skin aging includes one or more of improving skin photoaging, improving wrinkles, improving pigmentation, and improving skin sagging.

[0053] In some of these examples, the promotion of skin repair refers to activating the expression of SIRT1. Specifically, Bergapten can be used as a deacetylase SIRT1 activator to increase the activity of SIRT1 protein, and experiments have shown that Bergapten can activate the expression of SIRT1 protein, which is better than the recognized activator resveratrol.

[0054] In some of the examples, the promotion of skin repair refers to promoting the expression of collagen. Specifically, experiments have shown that Bergapten significantly inhibits the reduction of various collagen contents in skin keratinocytes caused by UV light aging stimulation.

[0055] In some of these examples, the promoting skin repair refers to promoting cell healing. Specifically, experiments have shown that Bergapten can promote the healing ability of cell scratches, promote skin wound healing, and accelerate repair.

[0056] In some examples, the collagen is one or both of Collagen Ⅰ and Collagen Ⅲ.

[0057] In summary, the present application discloses a novel application of SIRT1 activator in resisting skin photoaging, wherein the compound is composed of Bergapten or its isomers. The compound has the function of activating the aging-related protein SIRT1, while promoting the expression of various types of collagen in immortalized keratinocytes of human skin, promoting the healing ability of skin cells, and has no obvious side effects, and can be used to prepare applications related to anti-skin aging.

[0058] The following is further described in conjunction with specific embodiments. The raw materials involved in the following specific embodiments, unless otherwise specified, can all be commercially available; the instruments used, unless otherwise specified, can all be commercially available; the processes involved, unless otherwise specified, are all routinely selected by those skilled in the art.

[0059] Some of the raw materials used in the embodiment are as follows:

[0060] Human skin immortalized keratinocytes (HaCaT) were purchased from Zhejiang Meisen Cell Technology Co., Ltd.;

[0061] Resveratrol and Bergapten were purchased from MedChemExpress.

[0062] The positive control compound used in this application, resveratrol, is a non-flavonoid polyphenol organic compound and is an antitoxin produced by many plants when stimulated. Its chemical formula is C 14 H 12 O3, which can be synthesized in grape leaves and grape skins, is a biologically active ingredient in wine and grape juice. It is easily absorbed orally and excreted through urine and feces after metabolism. In vitro and animal experiments have shown that resveratrol has antioxidant, anti-inflammatory, anti-cancer and cardiovascular protective effects. Resveratrol can activate acetyltransferase and is a strong inducer of SIRT1. It can increase the expression of SIRT1 in organs and tissues such as the brain, heart, intestines, kidneys, muscles and fat. Resveratrol can cause physiological changes that delay aging and prolong life. Studies have shown that resveratrol is a substance that can support wound healing, eliminate excessive scars, and prevent skin photoaging.

[0063] The following are specific embodiments.

[0064] Example 1

[0065] 1. Cell culture: Immortalized human skin keratinocytes (HaCaT) were used in the experiment and fully mixed with DMEM complete medium at a rate of 1×10 6 / mL was inoculated in a 6cm cell culture dish and cultured in a cell culture incubator at 37℃, 5% CO2 and saturated humidity. The cells adhered to the wall and grew to cover 80% of the bottom area of ​​the culture dish. The subculture began. During the subculture, the original culture medium was aspirated, washed twice with PBS, digested with 0.25% trypsin, and left to stand in the cell culture incubator for 7 minutes. When the cells shrank and became round and gradually fell off the culture bottle, 2 times the volume of trypsin complete culture medium was added to stop digestion, the cell suspension was collected, centrifuged, and resuspended with an appropriate amount of complete culture medium. After counting, a certain concentration of cells was transferred to a new culture dish, 10mL of culture medium was added, and the cells were mixed to make them evenly spread in the dish.

[0066] 2. Cell drug treatment: When the cells reach the logarithmic growth phase, they are digested and counted, with 1×10 6 Cells were seeded in 6 cm culture dishes (5 × 10 5 in 6-well plate; 1×10 4 The cells were placed in a 96-well plate and placed in a CO2 incubator at 37°C, 5% CO2, and saturated humidity for 24 hours. After the cells adhered to the wall, the model group (UV group) and the drug-treated group were exposed to ultraviolet light for 90 minutes using an ultraviolet aging box UVA95%+UVB5% to simulate natural light, and then the culture medium was replaced. The model group was added with an equal amount of complete culture medium, and the drug-treated group was added with complete culture medium of each drug at the corresponding concentration. The cells were then placed in a cell culture incubator and cultured for the required time for subsequent experimental testing. The control group was not exposed to ultraviolet light or treated with drugs. The operation was similar to that of the model group after 90 minutes of ultraviolet irradiation, and the drug-free culture medium was replaced simultaneously.

[0067] The drugs used in the drug treatment group include resveratrol solution and Bergapten solution, and the preparation methods are as follows: resveratrol and Bergapten are respectively dissolved in dimethyl sulfoxide (DMSO) to prepare 10mM stock solutions, which are then diluted according to their respective working concentrations in the experiment.

[0068] 3. Drug safety test: When the density of drug-treated cells in the 96-well plate reaches about 80% of the bottom area of ​​the culture dish, replace the original drug-treated culture medium according to the ratio of CCK-8 reagent and cell culture medium (1:10), continue to culture in a CO2 incubator at 37°C, 5% CO2, and saturated humidity for 2 hours, detect the absorbance at a wavelength of 450nm, calculate the effect of the drug on the survival rate of the cells, and then judge the toxicity of the drug. The results are as follows Figure 1 As shown, the results indicate that Bergapten has no significant effect on cell viability within the concentration range of 0-3.5 μM, which is considered a safe concentration range.

[0069] 4. Detection of the effect of drugs on the expression of aging-related protein SIRT1 and various types of collagen: After UV stimulation of cell modeling, Bergapten (1μM) and resveratrol (1μM) were added to the drug treatment group to treat human immortalized keratinocytes for 24h. After that, the cells were collected, proteins were extracted, and used for WB (Western Blot) experiments. This application detected SIRT1 and various types of collagen Collagen Ⅰ and Collagen Ⅲ. By comparing with the control group, it can be judged whether the model group is successfully established. If the expression of SIRT1 and collagen in the model group is significantly reduced compared with the control group, the model is successfully established, otherwise it is unsuccessful. At the same time, the drug treatment group compares whether the expression of SIRT1 and collagen in the model group is increased to determine the activation effect of the drug on SIRT1 and promote the expression of collagen.

[0070] The results are as follows Figure 2-Figure 3 As shown in the figure, the results show that Bergapten can significantly activate the expression of SIRT1 and significantly promote the synthesis of collagen Ⅰ and collagen Ⅲ. At the same time, compared with the resveratrol positive drug control group at the same concentration, the activation effect of SIRT1 is stronger and the promotion effect of collagen expression is stronger.

[0071] 5. Detection of the effect of drugs on wound healing ability of cell scratches: Cells were seeded in 6-well plates (5×10 5 / well), cultured into a monolayer. When the cell fusion rate reached 100%, the culture medium was replaced after 90 minutes of ultraviolet irradiation using an ultraviolet aging box UVA 95% + UVB 5% to simulate natural light. Use a 200 μL sterile pipette tip to scratch the surface of the monolayer cells, and wash the floating cells remaining in the well with PBS. Take pictures under a microscope to record the area of ​​the scratch area. Bergapten (1μM) and resveratrol (1μM) were added to the drug treatment group, and human immortalized keratinocytes were cultured and treated with cell culture medium without fetal bovine serum for 24 hours. After the culture was completed, take pictures to record the area of ​​the scratch area for 24 hours.

[0072] The results are as follows Figure 4 As shown, the results showed that after UV irradiation, the healing ability of cell scratches was significantly reduced, while Bergapten and resveratrol could both promote the healing ability of cell scratches under UV irradiation, and the healing effect of Bergapten was higher than that of the resveratrol positive drug control group.

[0073] In summary, this application can obtain the following conclusions through effect experiments:

[0074] (1) This application first discovered that the compound Bergapten can activate the expression of SIRT1 protein and is superior to the recognized activator resveratrol;

[0075] (2) This application first discovered that the compound Bergapten can significantly inhibit the decrease in the content of multiple collagens in skin keratinocytes caused by UV light aging stimulation;

[0076] (3) This application discovered for the first time that the compound Bergapten can promote the healing ability of cell scratches.

[0077] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above-described embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0078] The above-described embodiments only express several implementation methods of the present application, and the descriptions thereof are relatively specific and detailed, but they cannot be construed as limiting the scope of the patent application. It should be pointed out that, for a person of ordinary skill in the art, several variations and improvements can be made without departing from the concept of the present application, and these all belong to the protection scope of the present application. Therefore, the protection scope of the patent application shall be subject to the attached claims, and the description may be used to interpret the content of the claims.

Claims

1. Use of Bergapten or its isomers in preparing products for improving skin aging and / or promoting skin repair.

2. The use according to claim 1, characterized in that: The products include cosmetics, food and medicines.

3. The use according to claim 2, characterized in that: The cosmetics include one or more of lotion, cream, emulsion, essence, facial mask and eye cream; The food includes one or more of functional food, beverage, health product and nutritional supplement.

4. The use according to claim 2, characterized in that: The dosage form of the drug includes oral solution, liquid suspension, powder, tablet, capsule, powder, mixture, pill, granule, syrup, plaster, suppository, aerosol, ointment or injection.

5. The use according to any one of claims 1 to 4, characterized in that: The product also includes auxiliary materials.

6. The use according to claim 5, characterized in that: The administration of the product includes oral administration and / or topical administration.

7. The use according to claim 6, characterized in that: The external application includes local administration and / or systemic transdermal administration.

8. The use according to any one of claims 1 to 4, characterized in that: The improvement of skin aging includes one or more of improving skin photoaging, improving wrinkles, improving pigmentation and improving skin sagging.

9. The use according to any one of claims 1 to 4, characterized in that: The promoting skin repair refers to activating the expression of SIRT1; and / or The said promoting skin repair refers to promoting the expression of collagen; and / or The said promoting skin repair refers to promoting cell healing.

10. The use according to claim 9, characterized in that: The collagen is one or both of Collagen Ⅰ and Collagen Ⅲ.

Images